Non-Small Cell Lung Cancer Market Projected to Reach USD 64.8 Billion by 2034
The Non-Small Cell Lung Cancer (NSCLC) market was valued at approximately USD 32 billion in 2025 and is projected to grow at an 8% CAGR, reaching USD 64.8 billion by 2034. Key markets analyzed include the US, EU4, and Japan.
The market for Non-Small Cell Lung Cancer (NSCLC) was valued at approximately USD 32 billion in 2025. This market is projected to expand at a compound annual growth rate of 8%, reaching an estimated USD 64.8 billion by the year 2034. Market growth is attributed to increasing disease prevalence and heightened awareness.
Market analysis by DelveInsight highlights the growing importance of biomarker-driven strategies in NSCLC treatment. The identification of Epidermal Growth Factor Receptor (EGFR) mutations is a key focus, with treatments like TAGRISSO targeting this biomarker already generating nearly USD 6 billion annually.
NSCLC accounts for about 80-85% of all lung cancer cases, with prevalence increasing in individuals aged 65 and older. The United States reported an estimated 204,800 new NSCLC cases in 2024. The report also includes data on the prevalence of other genetic subtypes, such as KRAS-mutated cancers, in Japan.
DelveInsight's report offers a comprehensive analysis of NSCLC epidemiology, market dynamics, and treatment patterns. The study covers major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. This intelligence aims to assist stakeholders in strategic decision-making, identifying investment opportunities, and planning research and development initiatives.